In a large study analysing the genomes of prostate cancer samples from 930 patients, researchers have found find no fewer than 80 new potential drug targets.

Analysis of prostate cancer mutations identified 11 targets of approved drugs, seven targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.

Extracting genetic data has become much quicker and cheaper. At the same time, the tools available for handling large datasets have vastly improved. Taken together, this means that the information harvested from the genetic code can be analysed with relative ease.

Once the researchers understood which genes were mutated and potentially causing the cancer, they were able to create a map of the proteins that are coded by the genes. This led them to identify the proteins that were potential drug targets.

According to Cancer Research UK prostate cancer is the most common cancer in males in the UK, with around 47,200 cases (26% of all new cancer cases) in 2015.

Recommended

'Keep Antibiotics Working' campaign returns

This year, a bespoke version of the successful 'non-prescription pad' has been developed specifically for pharmacists.

Ground breaking therapy for children with leukaemia

Up to 30 children a year in England with ALL are to be offered the CAR-T therapy, Kymriah.




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Independent Pharmacist's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.